The American Journal of Psychiatry

Park Royal Hospital Offers Inpatient & Outpatient Electroconvulsive Therapy

Retrieved on: 
Martedì, Novembre 7, 2023
The American Journal of Psychiatry, Patient, Suicide, Education, The Lancet, Psychiatry, Electricity, Fear, Electroconvulsive therapy, Risk, Suicidal ideation, ECT, Brain, Depression, Safety, American Journal, Anesthesia, Death, Mental health, Pharmaceutical industry

FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.

Key Points: 
  • FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.
  • At Park Royal Hospital, ECT is available on an inpatient and outpatient basis and is delivered by a trained team of professionals.
  • Electroconvulsive therapy involves using a mild electrical current to stimulate the brain to produce a brief seizure while the patient is under general anesthesia.
  • Those who are interested in receiving ECT at Park Royal Hospital do not need a referral to inquire about treatment and can begin the admissions process anytime.

TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs

Retrieved on: 
Martedì, Novembre 7, 2023
The American Journal of Psychiatry, Suicide, The Lancet, Psychiatry, Electroconvulsive therapy, Quality of life, Risk, Suicidal ideation, ECT, Depression, Safety, American Journal, Patient, Mental health, Pharmaceutical industry, Nursing

MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.

Key Points: 
  • MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.
  • TrustPoint Hospital offers inpatient and outpatient programs for patients who have a range of behavioral health concerns and need focused support.
  • ECT is available in all TrustPoint programs for adults age 18 and older.
  • “At TrustPoint Hospital, we’re committed to providing safe, efficient care that can positively transform patients’ quality of life,” said Brianna Motley, director of business development at TrustPoint.

Food and Drug Administration Approves First Postpartum Depression Pill, Research Led by Northwell Health’s Feinstein Institutes

Retrieved on: 
Lunedì, Agosto 7, 2023
Women, Biotechnology, Pharmaceutical, Health, FDA, Mental Health, Consumer, Clinical Trials, GABA, PPD, Medicine, JAMA, NAS, Feinstein Institutes for Medical Research, Neurochemistry, Woman, Multimedia, Research, Northwell Health, The American Journal of Psychiatry, Bangladesh Technical Education Board, American Medical Association, American Journal, Behavioural sciences, Journal, Patient, Zuranolone, Grammatical mood, Psychiatry, Credit, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIH, Medical research, Food, Safety, Allopregnanolone, Pharmaceutical industry, MD

View the full release here: https://www.businesswire.com/news/home/20230807136425/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230807136425/en/
    The national clinical trials for zuranolone were led by the Feinstein Institutes for Medical Research at Northwell Health.
  • “After years of dedicated research and collaboration with other scientists, women living with postpartum depression have a new, at-home, 14-day treatment option that has the potential to alleviate their symptoms,” said Dr. Deligiannidis.
  • Deligiannidis is a leader in clinical trials for postpartum depression, a condition that affects millions,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, Karches Family Distinguished Chair in Medical Research.
  • “The FDA approval stemming from her work will make available new therapeutic options that are clearly needed.”
    The Feinstein Institutes and Dr. Deligiannidis lead in researching new methods to diagnose and treat perinatal depression.

Novel investigational postpartum depression pill showed rapid and significant improvement in depressive symptoms in Phase 3 clinical trial

Retrieved on: 
Mercoledì, Luglio 26, 2023
Mental Health, Research, Women, Clinical Trials, Health Insurance, Health, Consumer, Pharmaceutical, Science, GABA, PPD, Perseverance, JAMA, Depression, Diarrhea, NAS, Feinstein Institutes for Medical Research, Somnolence, COVID-19, Food and Drug Administration, Clinical trial, Urinary tract infection, Woman, DSM-IV codes, Multimedia, The American Journal of Psychiatry, Mother, American Medical Association, American Journal, Behavioural sciences, Dizziness, Journal, Patient, Zucker Hillside Hospital, Zuranolone, Grammatical mood, Nausea, Paper, FDA, Headache, Credit, Northwell Health, Safety, Medical research, Food, Female, Pharmaceutical industry, Birth control, MD, Psychiatry

Fourteen-day oral, at-home, treatment with zuranolone versus placebo resulted in statistically significant improvement in depressive symptoms, as measured by change from baseline in HAMD-17 total score.

Key Points: 
  • Fourteen-day oral, at-home, treatment with zuranolone versus placebo resulted in statistically significant improvement in depressive symptoms, as measured by change from baseline in HAMD-17 total score.
  • Results showed that 57 percent of the women taking zuranolone versus 38 percent of women taking placebo experienced a 50 percent or more improvement in their depressive symptoms at day 15.
  • The trial demonstrated the improvement in depressive symptoms with zuranolone at 30 mg versus placebo in patients with PPD and that zuranolone was generally well tolerated.
  • The SKYLARK and ROBIN clinical trials provide some of the most substantial results for improving depressive symptoms in women with PPD.

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

Retrieved on: 
Giovedì, Luglio 13, 2023
Psilocybin, US Food Sovereignty Alliance, European Medicines Agency, Psychotherapy, Research, COMPASS, Thought, American Journal, Patient, The American Journal of Psychiatry, Psychiatry, CMPS, Mental health, Food, Safety, Nursing, Pharmaceutical industry, Medical device

Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.

Key Points: 
  • Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.
  • Authors highlight the need for clarity in terminology and definition to accurately assess the efficacy and safety of psilocybin treatment.
  • A therapist is present during the administration of psilocybin treatment to provide non-directive support, not to interpret the experience.
  • This clarity is important in the assessment of efficacy and safety of psilocybin, alongside standardized psychological support.

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

Retrieved on: 
Martedì, Ottobre 11, 2022
Quality of life, News, U.S. Securities and Exchange Commission, Caregiver, Insurance, ERP, Deep, TMS, Review, Policy, Obsessive–compulsive disorder, NASDAQ, Cigna, Patient, Obsessions, Income, Lists of diseases, Research, Psychotherapy, Mental health, TASE, Response, Blue Cross Blue Shield Association, Technology, Addiction, Knowledge, WHO, Private Securities Litigation Reform Act, Partnership, Trial of the century, Company, Tricare, Psychiatry, World, Health, Legislation, American Journal, CEO, Awareness, World Health Organization, Tic disorder, Transcranial magnetic stimulation, GLOBE, Failure, Brainsway, FDA, The American Journal of Psychiatry, Compulsions, OCD, Pharmaceutical industry, Health insurance, Medicare

This collaboration signifies an alignment of our collective goal to raise awareness and facilitate access to clinically proven treatment options for OCD.

Key Points: 
  • This collaboration signifies an alignment of our collective goal to raise awareness and facilitate access to clinically proven treatment options for OCD.
  • Stephen Smith, Cofounder and CEO of NOCD, said,NOCD is proud to partner with BrainsWay to raise OCD awareness and to help our community access additional OCD treatment interventions when needed.
  • BrainsWays collaboration with NOCD will help patients find the treatments they urgently need with access to ERP therapists and Deep TMS providers nationwide.
  • BrainsWay and NOCD will work together to increase awareness about OCD and the lifesaving treatments of both companies.

Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression

Retrieved on: 
Martedì, Settembre 6, 2022
Mental Health, Health, FDA, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Radiology, Medical University of South Carolina, Software, Structured Product Labeling, Mortality, CEO, Technology, Lists of diseases, Animation, Program, TMS, Disease, Brain, Randomized controlled trial, Medicine, Contraindication, Magnetic resonance imaging, Major depressive disorder, RCT, Multimedia, Hospital, Medical school, Depression, FDA, SAINT, Stanford University, News, Mental health, American Journal, MDD, MRI, Neuropsychiatric Disease and Treatment, The American Journal of Psychiatry, American Psychiatric Association, American, Behavioural sciences, Patient, Medical device, Medical imaging, Pharmaceutical industry, Magnus, Psychiatry, Neuroscience

View the full release here: https://www.businesswire.com/news/home/20220906005228/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220906005228/en/
    Magnus Medical is a developer of brain stimulation technology for the treatment of neuropsychiatric disorders.
  • Magnus Medical, Inc. , is a privately held medical device company driven to transform lives by restoring mental health.
  • Magnus first FDA-cleared product is the SAINT Neuromodulation System, which received FDA Breakthrough Device Designation for its novel, rapid-acting therapy for treatment-resistant depression.
  • The SAINT Neuromodulation System yields a new form of individualized neurostimulation for adults who have failed to achieve satisfactory improvement from prior antidepressant medications.

Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression

Retrieved on: 
Martedì, Luglio 12, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, Prevalence, Life, Safety, MDD, Health, Nutrition and cognition, Program, Thought, Depression, Deep brain stimulation, Grammatical mood, American Journal, LinkedIn, Patient, Journal, Review, Wi-Fi, Facebook, Food, Brain, Electrode, Physician, Parkinson's disease, Movement disorders, STAR, Essential tremor, Skin, TRD, Lists of diseases, FDA, Twitter, DBS, Unemployment, NYSE, The American Journal of Psychiatry, Medical device, Pharmaceutical industry, Psychiatry

Breakthrough Device Designation expedites the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.

Key Points: 
  • Breakthrough Device Designation expedites the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.
  • Abbott is working with the FDA to develop a plan for evaluating the device's safety and effectiveness for this purpose.
  • Currently, physicians have access to a range of treatments for MDD, also called clinical depression, including antidepressant medications and device therapies.
  • With Breakthrough Device Designation, Abbott's DBS system could become available as a new treatment option sooner for people affected by TRD.

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related Mental Health Disorders

Retrieved on: 
Mercoledì, Giugno 15, 2022
Regional Municipality of Waterloo, Rapids, Ta' Braxia Cemetery, SAP, COVID-19, Ketamine, Person, Controlled Drugs and Substances Act, IV, Company, Lists of diseases, TRD, Health Canada, Depression, Risk, OTC, CDSA, Forward-looking statement, Drug prohibition law, CSE, Psilocybin, Physician, The American Journal of Psychiatry, American Journal, Removal of cannabis from Schedule I of the Controlled Substances Act, News, Euro-Excellence Inc v Kraft Canada Inc, Psychiatry, Patient, Multimedia, Disorder, Kitchener–Waterloo Oktoberfest, Pharmaceutical industry, Hospital, Audit, Operation

The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada.

Key Points: 
  • The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada.
  • "Further plans are in place for the expansion of Braxia Health clinics in Toronto and Ottawa, Ont., to better serve the growing unmet need in our Canadian communities.
  • Additionally, Braxia Health clinics have begun to expand current offerings across its centers to include IV and oral ketamine.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

Retrieved on: 
Martedì, Maggio 31, 2022
Department, The Journal of Clinical Psychiatry, Lists of diseases, MDD, Journal, Patient, NASDAQ, Therapy, ASCEND, Depression, Dean (education), The American Journal of Psychiatry, Grammatical mood, CNS, Central nervous system, Major depressive disorder, Safety, Translational research, NMDA, NDA, American Journal, GEMINI, Massachusetts General Hospital, Harvard Medical School, Diagnosis, MD, GLOBE, Pharmaceutical industry, MADRS

The article, Efficacy and Safety of AXS-05 (dextromethorphan-bupropion) in Patients with Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI), was published in The Journal of Clinical Psychiatry and is available in full here .

Key Points: 
  • The article, Efficacy and Safety of AXS-05 (dextromethorphan-bupropion) in Patients with Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI), was published in The Journal of Clinical Psychiatry and is available in full here .
  • We are very pleased with the publication of the pivotal GEMINI trial results in The Journal of Clinical Psychiatry, a leading scientific journal, less than two weeks after the publication of the pivotal ASCEND trial results in The American Journal of Psychiatry, said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.
  • The article was published online in The Journal of Clinical Psychiatry in advance of the corresponding upcoming print issue.
  • A new drug application (NDA) for AXS-05 for the treatment of major depressive disorder is under review by the FDA.